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Expression profiling of human 
milk derived exosomal microRNAs 
and their targets in HIV‑1 infected 
mothers
Muhammad Atif Zahoor1,2,8*, Xiao‑Dan Yao1,2, Bethany M. Henrick3,4, Chris P. Verschoor1,2,5, 
Alash’le Abimiku6,7, Sophia Osawe6 & Kenneth L. Rosenthal1,2*
Despite the use of antiretroviral therapy (ART) in HIV‑1 infected mothers approximately 5% of new 
HIV‑1 infections still occur in breastfed infants annually, which warrants for the development of 
novel strategies to prevent new HIV‑1 infections in infants. Human milk (HM) exosomes are highly 
enriched in microRNAs (miRNAs), which play an important role in neonatal immunity. Furthermore, 
HM exosomes from healthy donors are known to inhibit HIV‑1 infection and transmission; however, 
the effect of HIV‑1 on HM exosomal miRNA signatures remains unknown. In this study, we used 
nCounter NanoString technology and investigated miRNAs expression profiles in first week 
postpartum HM exosomes from HIV‑1 infected and uninfected control mothers (n = 36). Our results 
indicated that HIV‑1 perturbed the differential expression patterns of 19 miRNAs (13 upregulated 
and 6 downregulated) in HIV‑1 infected women compared to healthy controls. DIANA‑miR functional 
pathway analyses revealed that multiple biological pathways are involved including cell cycle, 
pathways in cancer, TGF‑β signaling, FoxO signaling, fatty acid biosynthesis, p53 signaling and 
apoptosis. Moreover, the receiver operating characteristics (ROC) curve analyses of miR‑630 and miR‑
378g yielded areas under the ROC curves of 0.82 (95% CI 0.67 to 0.82) and 0.83 (95% CI 0.67 to 0.83), 
respectively highlighting their potential to serve as biomarkers to identify HIV‑1 infection in women. 
These data may contribute to the development of new therapeutic strategies in prevention of mother‑
to‑child transmission (MTCT) of HIV‑1.
Devastating statistics indicate more than 110,000 children die each year from HIV-1/AIDS related disorders 
and over 15,000 children are newly infected with HIV-1 every  month1, which make up a substantial proportion 
of the approximately 40 million people are currently living with HIV-1  worldwide1,2. Indeed mother-to-child 
transmission (MTCT) of HIV-1 is an important source of HIV-1 infection in infants and can occur in utero, 
during delivery and through breastfeeding. Prophylactic strategies have greatly reduced the risk of MTCT HIV 
transmission from 35% to less than 5%; however, new HIV-1 infection in infants who are breastfed by HIV-1 
positive mothers breastfeeding remains a major source of pediatric HIV-1 infection. Paradoxically, an interven-
tion that promotes exclusive breastfeeding, regardless of HIV status of the mother shows decreased vertical HIV 
transmission rates compared to infants who are non-exclusively  breastfed1,3. The mechanisms underlying this 
phenomenon remain unknown; however, data presented here may provide new insights into potential preventa-
tive and therapeutic strategies that may be useful for both infants and adults in the  future4.
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Importantly most of the infants born to HIV-1 positive women do not become infected themselves, which 
is potentially attributed to the anti-HIV-1 molecules present in human milk (HM)5,6. Previous work has shown 
specific HM exosomes, but not the plasma derived exosomes, had a protective effect by inhibiting HIV-1 infec-
tion of monocyte derived dendritic cells (MDDCs) and subsequent transfer to CD4+ T-cells. These data suggest 
that HM derived exosomes reduce the risk of MTCT of HIV-1 through  breastfeeding7. Exosomes are nanosized 
intraluminal extracellular vesicles secreted by a variety of cells that are present in almost all biological fluids. 
Moreover, they are specialized in long distance intracellular communication and facilitating the transfer of 
nucleic acids such as messenger RNAs (mRNAs) and microRNAs (miRNAs) for subsequent expression in target 
cells in a highly regulated and efficient  manner8,9. miRNAs are small, single-stranded, non-coding endogenous 
RNAs that suppress the target gene expression through translational  repression10–12 and in this manner, play a 
key role in diverse biological processes including proliferation, differentiation and  apoptosis13. Since miRNAs 
exist in plasma, urine, milk and other body  fluids14, they hold great promise to serve as useful biomarkers in 
various diseases including  cancer15–24.
Identification of HM exosomal miRNAs that play an important role in MTCT HIV-1 infection could be criti-
cal to our understanding of transmission; however, no studies exist that can document the expression profile 
of HM exosomes from HIV-1 infected women. Here, we investigated the expression profile of HIV-1 associ-
ated miRNAs in HM samples collected from HIV-1 infected women and identified a total of 19 miRNAs (fold 
change > 1.3; P < 0.05) which were differentially expressed in women infected with HIV-1 and targeted the cellular 
genes that are involved in multiple biological pathways including cell cycle, pathways in cancer, viral carcinogen-
esis, adherens junctions, TGF-β signaling, fatty acid biosynthesis, p53 signaling and apoptosis. Furthermore, our 
data indicated that two miRNAs, miR-630 and miR-378g could serve as biomarkers of HIV-1 infection. Taken 
together, these data identified important HM exosomal miRNAs which could be exploited in future studies for 
monitoring HIV-1 status in infected mothers as well as their potential role in the prevention of MTCT in infants.
Materials and methods
Human subjects. HIV-1-uninfected healthy control and HIV-1-infected women were recruited from 
the Plateau State, Nigeria to participate in the current study. All women were sampled during their voluntary 
‘healthy’ research visits as per the cohort  protocol25, and therefore, were not acutely ill at the time of sample col-
lection. Women who were included in the study, were not taking medications other than ART or vitamin supple-
ments intra- or post-partum and did not receive an epidural intra-partum. In addition, women were excluded if 
they had caesarean sections or they were diagnosed with mastitis post-partum.
Sample acquisition and preparation. HM samples were self-collected into sterile tubes within the first 
week and at one, three, and six months post-partum, and immediately shipped on ice for processing in our labo-
ratory. The samples were separated into lipid, skim milk supernatant, and cellular fractions and stored at − 80 °C 
and liquid nitrogen, respectively as previously  described26,27.
Exosome isolation from human milk. Exosomes were isolated from the skim milk supernatants using 
the Total Exosomes Isolation reagent (from other body fluids) as per manufacturer’s recommendations (Thermo 
Fisher, Canada). Briefly, 500 µl volume of each HM sample was centrifuged at 2000×g for 10 min (1st spin). 
Without disrupting the pellet, supernatant was transferred to a new tube and centrifuged again at 10,000×g 
for 30 min (2nd spin). The supernatant was transferred to a new tube and centrifuged at 10,000×g for 10 min 
(3rd spin). To the clear supernatant, 500  µl of 1 × PBS and 500  µl of exosome isolation reagent was added, 
vortex-mixed and incubated for 30 min at room temperature. After, incubation, the samples were centrifuged at 
10,000×g for 10 min and the supernatant was removed carefully and discarded. The exosomes in the pellets were 
dissolved in 50 µl of exosome resuspension buffer (Thermo Fisher, Canada), vortex-mixed and again centrifuged 
at 10,000×g for 5 min at room temperature. Without disturbing the non-organic particulate matter in the pellet, 
the supernatants containing the purified HM exosomes were transferred to a new tube and stored at – 20 °C 
until further use.
Transmission electron microscopy (TEM). HM derived exosomes morphology was evaluated by TEM 
through negative staining as  described28. Briefly, HM exosomes were placed onto formvar grids, fixed with 
2.5% glutaraldehyde, and contrasted with 1% uranyl acetate and finally visualized with a JOEL-1200EX trans-
mission electron microscope located at McMaster Electron Microscopy facility. The images with × 40,000–× 
300,000 magnifications were taken using AMTV600 computer program.
Western blotting. Exosomes were isolated from the HM samples as described above. Protein fraction was 
isolated, quantified using DC™ protein assay kit (Bio-Rad) and run on SDS-PAGE gel. Western blot analysis was 
performed with the primary antibody against CD81 (sc-166029; Santa Cruz) and HRP-labeled goat anti-mouse 
IgG 1706516 (Bio-Rad) as secondary antibody as  described26,27.
Exosome RNA isolation. Total RNA was extracted from the HM exosomes using Total Exosome RNA 
and Protein Isolation Kit as per manufacturer’s instructions (Invitrogen, Carlsbad, CA). Briefly, the isolated 
exosomes were dissolved in pre-warm 2 × denaturing solution followed by acid-phenol: chloroform extraction. 
The upper aqueous phase was precipitated with ethanol and total RNA was eluted with preheated (95 °C) elution 
buffer. The concentration of RNA was determined using the Nanodrop spectrophotometer (Nanodrop Tech-
nologies, Inc, Wilmington, Germany) as  described29 and were stored at − 80 °C until further use.
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NanoString nCounter miRNA profiling and data analysis. Before processing of the NanoString 
chip, RNA samples were analyzed with the Agilent Bioanalyzer 2100 and the RNA 6000 Nano LabChip Kit 
(Agilent, CA, USA). RNA samples which did not pass the quality check were excluded and replaced with new 
RNA samples, thus, only high quality RNAs were processed for miRNA NanoString profiling. Exosomal miRNA 
Figure 1.  Schematic layout of the methodology adopted for Human Milk Exosomal miRNA Profiling. Human 
milk samples were collected from HIV-1 infected and uninfected control women from Nigeria. The samples 
were processed for exosome isolation and confirmed either by electron microscopy or by Western blotting using 
Exosomal marker protein CD81. Exosomal RNAs were extracted, subjected to integrity check by Bioanalyzer 
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expression profiling was performed using the nCounter Human ver 3.0 miRNA Panel on nCounter Analysis 
System (NanoString Technologies) as  described30. A total of three cartridge chips were run at the same time each 
consisting of 12 samples (9 HIV-1 positive and 3 negative control per chip). For data analysis, HIV-1 positive 
and control samples were separately pooled. Raw NanoString counts were pre-processed and differential counts 
derived using the R package ‘edgeR’ (PMID: 19910308) as  described29,31. Briefly, counts were normalized using 
trimmed mean of M-values (TMM) method and miRNA that were less than the geometric mean of negative 
control probes for more than half of the samples were removed; the final miRNA count for differential expres-
sion analysis was 267. Differential expression between groups was calculated using the function exactTest, which 
is analogous to Fisher’s exact test, but adapted for overdispersed data (PMID: 19910308). Adjusted p-values were 
derived using Benjamini-Hochberg’s procedure for controlling false discovery rate. In order to predict the role 
of these miRNAs as a biomarker, Receiver Operating Characteristic (ROC) curves were generated for the top 
five miRNAs and their areas under the curve (AUC) were calculated using the R package “plotROC” (P < 0.001).
In‑silico bioinformatic analysis. For functional classification of miRNAs, DIANA-mirPath v3.0 was used 
for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) annotation analyses 
as  described32. DIANA-Tarbase and “Pathways Union” options were selected to perform a KEGG pathway analy-
sis using this database of experimentally validated targets. For GO analysis, miRNAs belonging to specific GO 
categories based on the experimental findings with “Categories Union” was conducted. The significance of each 
functional annotation term was generated using a modified Fisher’s exact test with P-value threshold of < 0.05 
Table 1.  Clinical characteristics of HIV-1-infected and uninfected mothers. *Number of deceased are shown 
in parenthesis.
Sr. no. ID no. Status Age HIV status (duration till 2017) ART (years) No. of previous pregnancies Live babies*
1 N-0379-M Control 30 – – 0 0
2 N-0380-M Control 30 – – 3 3
3 N-0382-M Control 26 – – 1 0 (1)
4 N-0353-M Control 30 – – 3 3
5 N-0356-M Control 31 – – 0 0
6 N-0364-M Control 37 – – 7 7
7 N-0369-M Control 31 – – 0 0
8 N-0371-M Control 29 – – 3 3
9 N-0374-M Control 32 – – 2 1 (1)
10 N-0230-M HIV-1 30 2014 (3 years) 3 0 0
11 N-0231-M HIV-1 35 2009 (8 years) 8 9 4 (5)
12 N-0232-M HIV-1 44 2006 (11 years) 11 5 3 (2)
13 N-0236-M HIV-1 35 2011 (6 years) 6 3 3
14 N-0247-M HIV-1 27 2013 (4 years) 4 2 2
15 N-0248-M HIV-1 30 2014 (3 years) 3 3 3
16 N-0249-M HIV-1 28 2011 (6 years) 6 2 0 (2)
17 N-0251-M HIV-1 29 2006 (11 years) 11 5 4 (1)
18 N-0254-M HIV-1 29 2008 (9 years) 9 1 1
19 N-0130-M HIV-1 31 2013 (4 years) 4 2 2
20 N-0138-M HIV-1 29 2011 (6 years) 6 3 1 (2)
21 N-0140-M HIV-1 39 2007 (10 years) 10 5 5
22 N-0160-M HIV-1 36 2014 (3 years) 3 6 5 (1)
23 N-0164-M HIV-1 24 2013 (4 years) 4 2 0 (2)
24 N-0178-M HIV-1 31 2007 (10 years) 10 3 2 (1)
25 N-0181-M HIV-1 28 2011 (6 years) 6 1 1
26 N-0192-M HIV-1 34 2008 (9 years) 9 0 0
27 N-0196-M HIV-1 29 2012 (5 years) 5 0 0
28 N-0207-M HIV-1 31 2006 (11 years) 11 7 5 (2)
29 N-0211-M HIV-1 35 2008 (9 years) 9 3 2 (1)
30 N-0222-M HIV-1 29 2010 (7 years) 7 0 0
31 N-0226-M HIV-1 30 2009 (8 years) 8 2 2
32 N-0233-M HIV-1 34 2006 (11 years) 11 4 4
33 N-0234-M HIV-1 26 2014 (3 years) 3 0 0
34 N-0238-M HIV-1 30 2014 (3 years) 3 7 5 (2)
35 N-0239-M HIV-1 32 2008 (8 years) 8 4 2 (2)
36 N-0240-M HIV-1 28 2002 (15 years) 15 2 1 (1)
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for KEGG pathways and < 1e−20 for GO analysis, respectively as  described32. The candidate target genes of the 
identified miRNAs were predicted using TarBase v8.033. The untranslated region (UTR) location was predicted 
by TargetScan v7.234. In order to identify the potential interactions of the differentially expressed miRNAs in 
HM from HIV-1 infected women, miRNA-mRNA Network analysis was performed using Network Analyst 
 software29 where miRNA to gene interaction data were collected from well-annotated databases such as miR-
TarBase v7.0, TarBase v7.0 and miRecords as  described35. For degree, betweenness and shortest Path, “all but 
miRNA nodes” filter option was selected for the analysis.
Ethics approval and consent to participate. Written as well as informed consent for the collection 
of demographics, behavioral data, and biological samples were obtained from all study participants. The study 
was approved by the McMaster Research Ethics Board (REB Approval #08-176), CCI of Children’s Hospital, Los 
Angeles, the institutional review boards of the University of Manitoba Hospital ethical review committee, Univer-
sity of Maryland Baltimore and Plateau State Specialist Hospital Nigeria Institutional Review Boards as described 
 previously25,27. All clinical investigations were conducted according to the principles of the Helsinki Declaration.
Results
Clinical characteristics of women participants. HIV-1 infected and uninfected women were recruited 
from the Plateau State, Nigeria as described  previously27,36 A total of 36 HM samples from the first week postpar-
tum (27 HIV-1 positive and 9 HIV-1 negative as controls) were processed for HM exosome miRNA profiling, as 
shown in the study layout in Fig. 1. The characteristics of the study population included in the current analyses 
Figure 2.  Human Milk Exosome characterization and RNA isolation. (A) Transmission electron micrograph 
of human milk exosomes demonstrates small vesicles with sizes ranging from 30 to 100 nm in diameter 
(Magnification: × 300,000; Scale bar 100 nm) (B) Western blotting for exosome-associated marker protein CD81. 
10, 20, and 40 µg of proteins from either freshly isolated or human milk exosomes kept at room temperature 
(RT) for 2 days were loaded (C) Electropherogram and (D) gel images of representative RNAs extracted from 
human milk exosomes run on Agilent 2100 Bioanalyzer. Lanes 1–9 correspond to 37–45 samples; L Ladder.
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are presented in Table 1. Of the 27 HIV-1 positive mothers, 22 were infected with HIV-1 for 4–15 years whereas, 
5 women were infected with HIV-1 for only 3 years. All HIV-1 positive women were receiving ART according 
to the regimen set by Nigerian Government and the  WHO37 and had CD4+ count ≤ 300/mm3 with undetectable 
viral load. It was impossible to obtain samples from ART-naïve HIV-1 positive women. Number of years on ART 
were counted, the day a woman was diagnosed positive for HIV-1 and placed on ART. As shown in Table 1, 13 
out of 22 HIV-1 positive women showed high infant mortality compared to uninfected. Additionally, infants 
born to HIV-1 positive women were found to be stunted and underweight similar to what has been described 
 previously25. 
Milk exosome characterization and RNA quality check. Exosomes were isolated from individual 
HM samples and confirmed by TEM. HM derived exosomes were 30–100 nm in size and largely spherical in 
shape (Fig. 2A). HM derived exosomes either freshly isolated or kept at room temperature for two days were 
confirmed using protein marker CD81 in a western blot analysis (Fig. 2B, Suppl Fig. S1). Next, exosomal RNA 
was isolated from HIV-1 positive and negative HM samples with an average yield of 40 ng/µl. The isolated RNA 
showed distinctive spikes of noncoding RNA bands at > 25 nucleotides (Fig. 2C,D).
Identification of HM derived exosomal miRNAs from HIV‑1 infected women. Expression of 41 
miRNAs were significantly different in HIV-1 positive compared to negative women (Fig. 3; P < 0.05). A com-
plete list of all 41 miRNAs is shown in Suppl Table S1. Specifically 13 miRNAs were significantly upregulated 
(P < 0.05; FC > 1.3; Table 2) including hsa-miR-320e; hsa-miR-630; hsa-miR-148a-3p; hsa-miR-23a-3p; hsa-miR-
378g; hsa-miR-30a-5p; hsa-miR-93-5p; hsa-miR-497-5p; hsa-miR-200b-3p; hsa-miR-200a-3p; hsa-miR-16-5p; 
hsa-miR-1262 and hsa-miR-4516. Conversely 6 miRNAs were downregulated in HIV-infected breast milk com-
pared to uninfected, including hsa-miR-422a; hsa-miR-644a; hsa-miR-520a-5p; hsa-miR-506-5p; hsa-miR-1257 
and hsa-miR-1253 (Table 2). Upon further analyses, mothers living with HIV-1 for 3 and 4–15 years showed 28 
Figure 3.  Differential expression of human milk exosome miRNAs in HIV-1 infected women. The differential 
expression profile of human milk exosomal miRNAs is shown as a volcano plot which demonstrates fold change 
versus significance (P < 0.05) to exhibit differences in the miRNA expression between HIV-1 infected and 
uninfected control women. The X-axis of the plot shows log-base two-fold change whereas Y-axis shows the log 
P-value. Red color indicates the level of significance (P < 0.05).
7
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12931  | https://doi.org/10.1038/s41598-020-69799-x
www.nature.com/scientificreports/
(18 upregulated; 10 downregulated) and 17 (10 upregulated; 7 downregulated) differentially regulated miRNAs, 
respectively which were not significantly different in terms of fold change (Suppl Tables S2, S3). From hereon, 
the prefix hsa was removed from the miRNAs.
Top ten miRNAs and their potential target genes. Since miRNAs act by directly silencing and/or 
reducing the expression of target genes, we next predicted the validated target genes of the top ten differen-
Table 2.  Differentially expressed human milk exosomal miRNAs in HIV-1 infected mothers.
Sr. no miRNA ID Log fold change Fold change p-value Adj. p-value Regulation
1 hsa-miR-320e 3.06611 8.375124 2.57E−03 0.124605 Up
2 hsa-miR-630 2.979453 7.886873 2.03E−05 0.005408 Up
3 hsa-miR-148a-3p 1.896117 3.7221 5.14E−04 0.068612 Up
4 hsa-miR-23a-3p 1.003622 2.005028 8.26E−03 0.207538 Up
5 hsa-miR-378g 0.866517 1.823256 1.24E−03 0.110628 Up
6 hsa-miR-30a-5p 0.834559 1.783312 1.96E−02 0.308391 Up
7 hsa-miR-93-5p 0.693353 1.617037 1.68E−02 0.279933 Up
8 hsa-miR-497-5p 0.682571 1.604997 1.02E−02 0.207538 Up
9 hsa-miR-200b-3p 0.580053 1.494904 2.82E−02 0.350687 Up
10 hsa-miR-16-5p 0.555462 1.469639 5.44E−02 0.386215 Up
11 hsa-miR-422a − 0.50323 1.41738 3.84E−02 0.381103 Down
12 hsa-miR-644a − 0.47998 1.394723 2.08E−03 0.124605 Down
13 hsa-miR-200a-3p 0.445082 1.361391 5.88E−02 0.386215 Up
14 hsa-miR-520a-5p − 0.40659 1.325552 3.27E−03 0.124605 Down
15 hsa-miR-506-5p − 0.39559 1.315479 5.92E−03 0.197641 Down
16 hsa-miR-1262 0.386293 1.307031 1.13E−02 0.207538 Up
17 hsa-miR-4516 0.386214 1.306959 1.10E−02 0.207538 Up
18 hsa-miR-1257 − 0.38522 1.306057 3.23E−03 0.124605 Down
19 hsa-miR-1253 − 0.38439 1.305306 2.43E−02 0.350687 Down
Table 3.  Tarbase v8.0 based target genes of the top ten differentially expressed human milk exosomal miRNAs 
in HIV-1 infected mothers. *Some of the target genes out of total are shown here in the table.
Sr. no. miRNA ID No. of interactions Target genes (gene symbols)* References
1 hsa-miR-320e 327
CDK6, MEGEA5, IGF2BP3, BTG2, WASF2, MINK1, SFPQ, PTBP1, BLMH, JUN, NUCKS1, CDK16, 
DYRK2, RTN4, CAND1, CLN6, MARCK5, RPL32, OAZ1, CSNK1A1, BAMBI, IRF3, DCAF7, ITGAV, 
BCL2L11, HNRNPU, DHX33, RNF10, UBE3C, WDR6, HERC1, NSD3
38,39
2 hsa-miR-630 3 BCL2, BCL2L2, YAP1 40
3 hsa-miR-148a-3p 1,481
DNMT1, IGF1R, IRS1, ITGB8, BCL2L11, DCAF7, RAB1B, USP28, CDKN1B, ZNF460, TNRC6A, 




ZNF91, CXCL12, LAMP1, IFNG, CDK17, CDK1, HDAC7, TCF20, MTMR2, TOP2B, VACN, TRIB1, 
UBL3, FUT9, TSNAX, TJP2, AHNAK, TNRC6A, ZNF107, CBX5, CREBZF, SESN3, UFM1, EIF2A, 
STX12
13,45,46
5 hsa-miR-378g 123 TAOK1, PPP1R37, VE2F1, SP4, CBLC1, MBP, PSMD8, PABPC3, BLOC1S6, WDR5, SMAD2, FKBP4, PIAS1, KCTD20, PSMD8, TNRC6C, PAPOLA, CREBBP, CDH1, TARBP2, HIVEP3
42,47
6 hsa-miR-30a-5p 2,808
TNRC6A, DDIT4, RHOB, E2F7, BRWD1, NDEL1, DHX36, FBXO45, RPA2, XRN1, SOCS1, PLA2G12A, 
IFNGR2, DCAF12, ATG12, ERLIN1, NOTCH1, BECN1P1, DDAH1, MAST4, AGO2, SOX4, IPO4, 




CDKN1A, CSKN1A1, CLIP1, ANKIB1, BACH1, CLTC, ULK1, DZAPAP2, CCND1, PELI1, MOB1A, 
E2F1, PIK3R1, RAB22A, IRF9, TNKS2, MAPK1, TXN, TMEM138, USP31, RRM2, MKNK2, PFN2, 
PURA, ADAM9, ZNFX1, RUFY2, TXNIP, SEMA7A, JAK1, CNOT4, WEE1, BNIP2, IPO7, RAB5B
42,43,47,49,50
8 hsa-miR-497-5p 1,590
CCND1, CCNE1, E2F3, CDK6, ACTB, CCND3, CDk4, CDC25A, BTRC, TXNIP, FBXW7, ABI2, BTG2, 
WEE1, HSPA1B, ARL2, CSDE1, CCND1, CDCA4, BTG2, ATG9A, PDCD4, SESN3, SMAD2, NOTCH2, 
IGF1R, DDX6, MAPK8, PURA, TLK1, TACC1, HIPK2, BCL2L2
45,47,51
9 hsa-miR-200b-3p 1905
TCF7L1, ERBB21P, VAC14, RASSF2, NOTCH1, CDKN1B, AKAP11, CAB39, ANKRD42, ETS1, KRAS, 




TLR4, HIST1HIC, WEE1, DNAJB4, JUN, NUFIP2, CCND1, RRHGDIA, TNRC6A, LATS1, KIF21A, 
CDCA4, TLR6, DDX17, PSAT1, PRAGA, ODC1, SP1, CDK6, SMAD2, LAMP2, RBF217, XPO7, 
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tially expressed miRNAs using a well characterized database (Tarbase v8.0)33. Our results indicated a total of 
19895 interactions (Table 3). miR-16-5p was found to target the largest number of genes including IRF9, TLR4, 
TLR6 and JUN. miR-630 was shown to target BCL2, BCL2L11 and YAP1. miR-378g was shown to target 123 
genes including SMAD2, CREBBP and WDR5. Interestingly, multiple miRNAs including miR-320e and miR-
148a-3p targeted BCL2L11 and miR-630 and miR-497-5p both targeted BCL2L2. miRNAs, miR-30a-5p and 
miR-200b-3p, targeted NOTCH1, while miR-378g, miR-497-5p and miR-16-5p targeted SMAD2 (Table 3).
GO and KEGG pathways. KEGG pathway analysis on the predicted targets led to the identification of 31 
significant pathways in which the predicted miRNA targets were enriched (Fig. 4). Specifically, miRNA targets 
associated with HIV-1 belonged to multiple pathways such as pathways in cancer, viral carcinogenesis, adherens 
junctions, TGF-β, fatty acid biosynthesis, p53 signaling, cell cycle, pathways regulating pluripotency of stem cells 
and proteoglycans in cancer (Fig. 4). Next, we performed GO analysis to identify the biological processes associ-
ated with the miRNAs. A total of 30 GO biological processes were observed (Fig. 5). The highest enrichment GO 
terms targeted by these miRNAs included biosynthetic process followed by viral process, catabolic process, cell 
death, ion binding, membrane organization, mitotic cell cycle, RNA metabolic process, poly (A) RNA binding 
and neurotropin TRK receptor signaling pathway (Fig. 5).
miRNA–gene interaction network. To understand the association of differentially expressed miRNAs 
in HIV-1 infected HM and their target proteins, miRNA-gene interaction network was generated using miRNet 
tool. The 19 differentially expressed miRNAs were uploaded into miRNet platform and miRNA-gene interac-
tions were observed which generated 4190 target nodes and 6042 edges. Shortest path filter with “all but miRNA 
Figure 4.  KEGG Pathway analysis of differentially expressed human milk exosome miRNAs. Differentially 
expressed exosomal miRNAs in HIV-1 infected human milk regulate multiple cellular pathways. Depicted here 
in the heatmap, significant pathways generated by DIANA-miRPath v3.0 software using Tarbase database are 
shown on the X-axis whereas miRNAs are shown on the Y-axis. The color code represents the log (P-value), 
with the most significant predicted miRNA-pathway interactions in red.
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nodes” generated 124 nodes with 105 targets and 393 edges (Fig. 6). The top cluster hubs included miR-16-5p fol-
lowed by miR-497, miR-93-5p, miR-30a-5p and miR-23a-5p. The biological functions were determined within 
the “reactome database” using the “hypergeometric test” algorithm and P-value < 0.05. Results showed that pre-
notch transcription and translation (TP53, E2F3, AGO2, CCND1) was the top group followed by mitotic G1/S 
phase (Wee1, CDK6, CDKN1A, E2F3, PSMD11, CCND1, CCNE2), cyclin D associated events in G1 (E2F3, 
CDK6, CDKN1A, CCND1), EGFR signaling (EGFR, GRB2, HSP90AA1), Intrinsic pathway of apoptosis (BCL2, 
XIAP, TP53, DYNLL2) and cell cycle (BIRC5, CCND1, CDK6, CDKN1A, CCNE2, WEE1, TP53, PSMD11, 
PAFAH1B1, HSP90AA1, E2F3, TAOK1, FOXM1, CSNK2A1). Collectively, these results demonstrate the target 
genes of miRNAs perturbed by HIV-1 belong to multiple biological pathways.
miR‑630 and miR‑378g as biomarkers of HIV‑1 infection. In order to evaluate the utility of exosomal 
miRNAs in HM as a potential diagnostics, we performed ROC curve analysis of the top 5 miRNAs in discrimi-
nating HIV-1 infected women from healthy controls. This analysis showed that miR-320e, miR148a-3p, miR-
378g, miR-630 and miR-23a-3p were substantially increased in HIV-1 infected breast milk and showed ROC 
AUC values of 0.75 (95% CI 0.58 to 0.75), 0.79 (95% CI 0.6 to 0.75), 0.83 (95% CI 0.67 to 0.83), 0.82 (95% CI 0.67 
to 0.82) and 0.72 (95% CI 0.55 to 0.72) respectively (Fig. 7). Furthermore, when miR-630 and miR-378g were 
combined, it yielded ROC AUC of 0.86 (95% CI 0.72 to 0.86) (Fig. 7) suggesting that miR-630 and miR-378g 
could serve as biomarkers to distinguish HIV-1 infected HM from non-HIV-1 infected HM.
Figure 5.  Gene Ontology Analysis of differentially expressed human milk exosome miRNAs. Gene Ontology 
of differentially expressed exosomal miRNAs in HIV-1 infected human milk is shown as heatmap which was 
created by DIANA-miRPath v3.0 software using Tarbase database. The heatmap enables similar miRNAs to 
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Schematic model showing miR‑378g mediated HIV‑1 transactivator (TAR) binding protein 2 
(TARBP2) depletion and its predicted role in HIV‑1 infection. TargetScan predicts the targets of 
miRNAs by searching for the presence of conserved 8-mer, 7-mer and 6-mer sites that match the seed regions of 
each  mRNA13. Using the search term HIV, we identified that miR-378g has one target site in 3′ UTR of TARBP2 
(ENST 00000552857.1) from 382 to 388 (Fig. 8A). TARBP2 is known to promote HIV-1 LTR expression and 
viral production whereas its siRNA-mediated knockdown inhibits HIV-1 LTR expression and viral  production55. 
A schematic of the hypothetical layout is shown in Fig. 8B, where we speculate that miR-378g mediated RNA 
interference would lower HIV-1 expression and viral production essentially as previously  described56.
Discussion
HIV-1 is known to cause dramatic changes in cellular miRNA expression  profiles57–60, however its effect on 
HM derived exosomal miRNAs remains unknown. Here, we characterized miRNA expression profiles of HM 
exosomes derived from HIV-1 infected HM and showed that HIV-1 infection significantly altered the expres-
sion levels of exosomal miRNAs. Analysis of differentially expressed miRNAs by a gene ontology and KEGG 
pathway-based approach revealed several biological processes are affected by HIV-1 infection. Furthermore, we 
identified two dysregulated miRNAs that can potentially discriminate HIV-1 positive HM from uninfected HM, 
with good predictive power. Collectively, these data provide, for the first time, comprehensive insight into HM 
exosomal miRNA profiles involved during HIV-1 infection.
Figure 6.  Network analysis of differentially expressed miRNAs and their target genes in HIV-1 infected human 
milk. Network display showing differentially expressed miRNAs (Fold change 1.3; P < 0.05) and their target 
genes in HIV-1 infected human milk. Cluster hubs shown in blue squares indicate miRNAs whereas red circles 
depict their target genes.
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Our data are timely given exosomes have recently emerged as new players in HIV-1 infection, albeit their 
exact role in HIV-1 pathogenesis and transmission is not completely  understood20,59. Importantly, exosomes may 
act at different levels of HIV-1 pathogenesis by modulating immune responses, infectivity or possibly activating 
latent viral  reservoirs9. Indeed, the impact of exosomes on HIV-1 has been suggested as a potential strategy to 
cure HIV-1 infection and/or  therapeutic61. Currently, only a few reports exist that demonstrate the immune-
modulatory functions of HM derived  exosomes62 which may partly be due to the methodological limitations in 
their isolation and  purification8. In this study, we have provided a successful HM exosome isolation method that 
will potentially aid future studies related to HM derived exosome characterization and mechanism.
To gain more insight into HM derived exosomal miRNAs modulation by HIV-1, we performed NanoString 
miRNA profiling and showed that HIV-1 perturbed the expression levels of 19 miRNAs (FC > 1.3; P < 0.05; 
Table 2). Further, we identified 31 KEGG pathways potentially regulated by miRNAs including pathways in 
cancer, TGF-β, fatty acid biosynthesis, FoxO signaling, p53 signaling, cell cycle, pathways regulating pluripotency 
of stem cells and proteoglycans in cancer. miRNA-mRNA network showed differentially expressed miRNAs are 
linked to each other via their target genes. Furthermore, miRNA-mRNA network analysis, in addition to cell 
cycle, apoptosis identified the involvement of NOTCH and EGFR pathways.
A combination of two miRNAs (miR-630 and miR-378g) had 86% accuracy rate in predicting HIV-1 infection 
which may serve as a biomarker for segregating HIV-1 positive HM from uninfected HM. The stability of HM 
exosomes at room temperature also raises the possibility of their utility in initial screening processes prior to 
HIV-1 specific blood testing in low-to-middle income countries. Mothers living with HIV-1 for 3 and 4–15 years 
showed no significant fold change differences in miRNA expression levels (Suppl Tables S2, S3). Furthermore, the 
majority of women who participated in the study were carrying HIV-1 for greater than 5 years (Table 1), thus it 
is suggested these two miRNAs could be used to monitor AIDS progression in HIV-1 infected women. Indeed, 
our finding is in agreement with a previous study in which miR-630 was reported as a biomarker in chronic 
progressors of HIV-163. Interestingly, our HM exosomal miRNA data from the South Africa cohort where HIV-1 
infected women were carrying HIV-1 load < 1 year (data not shown) showed downregulation of these miRNAs 
identified in the current study and correlated with a recent report where it was shown that acute HIV-1 leads 
Figure 7.  ROC curve analysis of human milk exosome miRNAs. ROC curves for the individual top five 
(miRNA-320e, miRNA-148a-3p; miRNA-378g, miRNA-630 and miRNA-23a-3p) or combined miRNAs 
(miRNA-630 and miRNA-378g) for discriminating HIV-1 infected women from healthy controls. ROC receiver 
operating characteristic, AUC area under the ROC curve.
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to downregulation of  miRNAs57. Nonetheless, miRNA data shown here could be used for future studies to gain 
more insight into HIV-1 pathogenesis.
miRNAs are thought to be involved in mediating immune suppression, establishment of viral  latency59,64 
or suppressing HIV-1 replication via decreasing HIV-1 dependency  factors65. Some of the miRNAs we have 
identified have previously been implicated in HIV-1 infection including miR-630, miR-4516, miR-16-5p, miR-
378, miR-93, miR-23, miR-30a57,63,66–69 thus strongly suggesting the reliability of the NanoString data obtained 
in the current study. Further, it has been described that NanoString can perform miRNA profiling with digital 
precision and the results do not require further validation by another  method70. miRNA-630 causes apoptosis by 
targeting BCL2, BCL2L2 and IGF-1R71 or maintains the apoptotic balance by targeting multiple  modulators72. 
Figure 8.  Schematic model showing miR-378g mediated TARBP2 depletion and inhibition of HIV-1 
replication. (A) Target nucleotide sequence of 3′ UTR of Human TARBP2 (ENST00000552857.1) recognized 
by miR-378g as confidently annotated by TargetScan v7.2. Predicted consequential pairing of target region is 
shown in the top and miRNA-378g sequence in the bottom. (B) TARBP2, a cellular protein originally identified 
as a binding partner of HIV-1 LTR (transactivation response element found at both 5′ and 3′) and is well known 
to enhance HIV-1 expression and virus production, once depleted by host cellular miR-378g would presumably 
lower the HIV-1 expression and virus  production55.
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miR-15a/b, miR-16, miR-20a, miR-93, miR-106b have been shown to bind Pur-α and repress its  expression68. 
Pur-α is a cellular partner for Tat regulatory protein of HIV-1 and facilitates its transcriptional  activity73,74 and 
is required for HIV-1 infection in  macrophages68,75. We found that Pur- α is a target of HM exosomal miR-93-5p 
and miR-497-5p. Whether HM exosomal miR-93-5p and miR-497-5p lower the R5-tropic HIV-1 infection of 
macrophages is not known but will be intriguing to investigate in future studies.
HM derived immunomodulatory factors are transferred from mothers to infants via breastmilk which include 
immunoglobulins, cytokines, chemokines, growth factors, hormones, lactoferrins and Toll-like  receptors26,27,76–80. 
TGF-β is a major cytokine in HM that favors preferential MTCT of R5-tropic HIV-181,82. miR-378g, miR-16-5p 
and miR-497-5p were found to target SMAD2 which has previously been shown to mediate TGF-β and regulate 
multiple pathways such as cell proliferation, apoptosis and cellular  differentiation81,83. HIV-1 positive human skim 
milk fraction after heat inactivation and proteolytic digestion retains HIV-1 inhibitory activity and was shown 
to significantly inhibit oral HIV-1 transmission in-vivo3. Since, HM exosomal miRNAs are known to reach the 
systemic  circulation62, these data suggest the HM derived exosome containing miRNAs reported herein may 
reach the fetal systemic circulation via breastmilk and play an important role in lowering MTCT of HIV-17. 
Further future studies are required to elucidate the functional role of these HM exosomal miRNAs.
Using a consensus scoring approach, it has been shown that miR-378 targets HIV-1 envelope  gene67. mir-378 
family consist of 11 mature miRNA members according to miRbase database (www.mirba se.org) comprising of 
miR-378a-5p, miR-378a-3p, miR-378b, miR-378c, miR-378d, miR-378e, miR-378f, miR-378g, miR-378h, miR-
378i and miR-378j; however, this study is the first to indicate the involvement of miR-378g in HIV-1 infection. 
Furthermore, prediction analysis suggested miRNA-378g targets a site located in 3′ UTR of TARBP2 from 382 
to 388 nucleotides (Fig. 8), which is required for HIV-1 expression and virion  production55,84. Interestingly, 
astrocytes are shown to be resistant to HIV-1 infection due to low endogenous levels of  TARBP285. TARBP2 
was originally identified as a protein that binds to the 59 nucleotides conserved TAR element found at the 5′ 
and 3′ ends of all HIV-1 transcripts and enhances its translation and  replication56,84,86. In addition, miR-378g 
was also found to target 4 confidently annotated sites in 3′ UTR of human HIV-1 enhancer binding protein 3 
(HIVEP3) (ENST00000372583.1) located at 582–588, 2026–2032, 2208–2214 and 2580–2586 nucleotides (data 
not shown). Although, the role of HIVEP3 in HIV-1 replication is not clear, targeting HIVEP2 by miRNAs is 
known to reduce HIV-1  replication87. The effect of miR-378g on HIV-1 replication and MTCT must be inves-
tigated in future studies.
HIV-1 associated neurologic disease (HAND) occurs in more than 25% of HIV-1 infected patients who 
develop  AIDS88. Previously, miR-4516 has been shown to be a biomarker of HAND in HIV-1 infected  patients66. 
Our data showed that miR-4516 is upregulated in 4–15 years HIV-1 infected HM which may suggest HIV-1 
infected women were HAND-asymptomatic or already had developed HAND. Although, our clinical data did 
not collect any neurologic symptoms in these infected women, it will be interesting to monitor the immune status 
as well as the temporal expression pattern of miR-4516 in future studies.
In conclusion, these data are the first to characterize the expression of HM exosomal miRNAs in HIV-1 
infected HM. Given the use of current ART in HIV-1 positive mothers does not completely mitigate MTCT 
of HIV-1, interventions including the use of exosomal miRNA in addition to available ART may be required 
to prevent new infections of HIV-1 in infants. In this context, our data detailing HM exosome miRNAs could 
potentially be exploited to lower MTCT HIV-1 transmission. Moreover, the miRNAs reported herein may serve 
as potential biomarkers of HIV-1 infected HM.
Data availability
The datasets reported and analyzed in the current study are available in NCBI Gene Expression Omnibus (GEO) 
repository and are accessible through GEO series accession number GSE143039.
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Adj. p-value Regulation 
1 hsa-miR-320e 3.06611 8.375124 2.57E-03 0.124605 UP 
2 hsa-miR-630 2.979453 7.886873 2.03E-05 0.005408 UP 
3 hsa-miR-148a-3p 1.896117 3.7221 5.14E-04 0.068612 UP 
4 hsa-miR-23a-3p 1.003622 2.005028 8.26E-03 0.207538 UP 
5 hsa-miR-378g 0.866517 1.823256 1.24E-03 0.110628 UP 
6 hsa-miR-30a-5p 0.834559 1.783312 1.96E-02 0.308391 UP 
7 hsa-miR-93-5p 0.693353 1.617037 1.68E-02 0.279933 UP 
8 hsa-miR-497-5p 0.682571 1.604997 1.02E-02 0.207538 UP 
9 hsa-miR-200b-3p 0.580053 1.494904 2.82E-02 0.350687 UP 
10 hsa-miR-16-5p 0.555462 1.469639 5.44E-02 0.386215 UP 
11 hsa-miR-422a -0.50323 1.41738 3.84E-02 0.381103 DOWN 
12 hsa-miR-644a -0.47998 1.394723 2.08E-03 0.124605 DOWN 
13 hsa-miR-200a-3p 0.445082 1.361391 5.88E-02 0.386215 UP 
14 hsa-miR-520a-5p -0.40659 1.325552 3.27E-03 0.124605 DOWN 
15 hsa-miR-506-5p -0.39559 1.315479 5.92E-03 0.197641 DOWN 
16 hsa-miR-1262 0.386293 1.307031 1.13E-02 0.207538 UP 
17 hsa-miR-4516 0.386214 1.306959 1.10E-02 0.207538 UP 
18 hsa-miR-1257 -0.38522 1.306057 3.23E-03 0.124605 DOWN 
19 hsa-miR-1253 -0.38439 1.305306 2.43E-02 0.350687 DOWN 
20 has-miR-503-5p -0.36753 1.290142 8.58E-03 0.207538 DOWN 
21 has-miR-590-5p -0.34374 1.269041 1.17E-02 0.207538 DOWN 
22 hsa-miR-513a-3p 0.338847 1.264746 2.89E-02 0.350687 UP 
23 hsa-miR-143-3p -0.32445 1.252189 3.59E-02 0.381103 DOWN 
24 hsa-miR-335-5p 0.322646 1.250623 4.50E-02 0.386215 UP 
25 hsa-miR-185-5p 0.317821 1.246446 3.05E-02 0.354176 UP 
26 hsa-miR-411-5p -0.31197 1.241402 2.87E-02 0.350687 DOWN 
27 hsa-miR-371a-5p -0.31176 1.241222 2.69E-02 0.350687 DOWN 
28 hsa-miR-592 -0.31002 1.239725 4.28E-02 0.381103 DOWN 
29 hsa-miR-1305 0.307194 1.237299 4.23E-02 0.381103 UP 
30 hsa-miR-665 -0.3071 1.237222 4.02E-02 0.381103 DOWN 
31 hsa-miR-767-5p 0.307007 1.237139 3.44E-02 0.381103 UP 
32 hsa-miR-605-5p -0.30419 1.234721 4.77E-02 0.386215 DOWN 
33 hsa-miR-526a -0.30222 1.233041 8.86E-03 0.207538 DOWN 
34 hsa-miR-301a-5p 0.295249 1.227096 4.77E-02 0.386215 UP 
35 hsa-miR-572 -0.29462 1.226562 5.49E-02 0.386215 DOWN 
36 hsa-miR-891a-5p 0.293378 1.225506 4.16E-02 0.381103 UP 
37 hsa-miR-603 -0.27671 1.211433 5.07E-02 0.386215 DOWN 
38 hsa-miR-181b-2-3p -0.25943 1.197003 5.24E-02 0.386215 DOWN 
39 hsa-miR-3065-5p -0.25895 1.19661 5.77E-02 0.386215 DOWN 
40 hsa-miR-1307-5p -0.25636 1.194459 5.86E-02 0.386215 DOWN 
41 hsa-miR-149-5p -0.23239 1.174782 5.93E-02 0.386215 DOWN 
 
 
Suppl Table 2: Differentially expressed human milk exosomal miRNAs in mothers 
living with HIV-1 for 3 years 
 
Sr. 

















1 hsa-miR-320e 2.99814 7.989734 2.01E-07 2.86E-05 UP 
2 hsa-miR-630 2.79309 6.931138 3.31E-17 9.42E-15 UP 
3 hsa-miR-30a-5p 1.19366 2.287336 4.91E-06 0.00035 UP 
4 hsa-miR-378g 0.96032 1.945747 1.49E-06 0.000142 UP 
5 hsa-miR-93-5p 0.84462 1.795798 0.001015 0.048212 UP 
6 hsa-miR-23a-3p 0.74021 1.670429 0.000385 0.02197 UP 
7 hsa-miR-200b-3p 0.63601 1.55403 0.005171 0.210542 UP 
8 hsa-miR-126-3p 0.58374 1.498736 0.00678 0.241539 UP 
9 hsa-miR-125b-5p 0.54454 1.458565 0.025566 0.383462 UP 
10 hsa-miR-497-5p 0.52191 1.435855 0.013069 0.353251 UP 
11 hsa-miR-16-5p 0.50573 1.419848 0.022313 0.383462 UP 
12 hsa-miR-335-5p 0.45799 1.373632 0.014574 0.353251 UP 
13 hsa-miR-301a-5p 0.45773 1.373382 0.01865 0.379668 UP 
14 hsa-miR-26b-5p 0.44300 1.359437 0.010608 0.335919 UP 
15 hsa-miR-200a-3p 0.43390 1.350889 0.048097 0.502367 UP 
16 hsa-miR-423-5p 0.42813 1.34549 0.044136 0.502367 UP 
17 hsa-miR-1305 0.42790 1.345278 0.020503 0.383462 UP 
18 hsa-miR-185-5p 0.42646 1.343937 0.031616 0.409575 UP 
19 hsa-miR-526a -0.36935 1.291776 0.049355 0.502367 DOWN 
20 hsa-miR-379-5p -0.40747 1.326367 0.024573 0.383462 DOWN 
21 hsa-miR-574-5p -0.40864 1.327438 0.039971 0.474658 DOWN 
22 hsa-miR-143-3p -0.41213 1.330652 0.028015 0.383462 DOWN 
23 hsa-miR-603 -0.41222 1.330734 0.039716 0.474658 DOWN 
24 hsa-miR-488-3p -0.43444 1.351395 0.02764 0.383462 DOWN 
25 hsa-miR-3613-5p -0.43540 1.352294 0.046911 0.502367 DOWN 
26 hsa-miR-506-5p -0.46611 1.381381 0.028255 0.383462 DOWN 
27 hsa-miR-520a-5p -0.51127 1.425313 0.014874 0.353251 DOWN 
28 hsa-miR-3065-3p -0.55251 1.466642 0.016362 0.3587 DOWN 
 
  
Suppl Table 3: Differentially expressed human milk exosomal miRNAs in mothers 
living with HIV-1 for 4~15 years 
 
Sr. 
















1 hsa-miR-630 2.979356 7.886338 4.72E-05 0.012542 UP 
2 hsa-miR-320e 2.691412 6.459455 0.008524 0.228975 UP 
3 hsa-miR-148a-3p 1.949454 3.862282 0.000549 0.073056 UP 
4 hsa-miR-23a-3p 1.088058 2.125877 0.007968 0.228975 UP 
5 hsa-miR-378g 0.85723 1.811556 0.003007 0.159951 UP 
6 hsa-miR-497-5p 0.722375 1.649896 0.00837 0.228975 UP 
7 hsa-miR-200b-3p 0.55742 1.471636 0.043302 0.470288 UP 
8 hsa-miR-4516 0.418151 1.336214 0.008818 0.228975 UP 
9 hsa-miR-1262 0.402436 1.321737 0.010675 0.228975 UP 
10 hsa-miR-513a-3p 0.372453 1.294552 0.022486 0.351833 UP 
11 hsa-miR-506-5p -0.3675 1.290111 0.014512 0.27573 Down 
12 hsa-miR-503-5p -0.37601 1.297746 0.009746 0.228975 Down 
13 hsa-miR-520a-5p -0.37923 1.30065 0.007939 0.228975 Down 
14 hsa-miR-1253 -0.40407 1.32324 0.025619 0.364158 Down 
15 hsa-miR-1257 -0.43195 1.349059 0.00143 0.12677 Down 
16 hsa-miR-644a -0.50783 1.421913 0.002051 0.136418 Down 
17 hsa-miR-422a -0.54413 1.458139 0.037247 0.450354 Down 
 
  
Suppl Figure 1: Western Blot Confirmation of Human Milk Exosomes: Western 
blotting for exosome-associated marker protein CD81. 10, 20, and 40 µg of proteins from 
either freshly isolated or human milk exosomes kept at room temperature (RT) for 2 days 
were loaded (Top and bottom Images with different exposure times).  
 
